Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerAnastasia Wyce(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States))OncotargetNovember 23, 201310.18632/oncotarget.1572Cited by 177SaveCiteExport RISWatch citationsRelated PapersActivation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing|Scientific Reports|2018|205